KURA ONCOLOGY INC

Insider sell‑to‑cover by Kura Oncology’s legal chief shows routine tax‑cover activity, not a confidence shift—focus remains on pre‑clinical progress.

Insider buying by KURA Oncology’s CSO signals confidence in its pancreatic and blood‑cancer pipeline, hinting at potential price support amid market volatility.

CEO Troy Edward’s recent Kura Oncology share buy shows strong confidence and aligns management’s interests, hinting at a bullish future.

Investors weigh KURA Onco’s CEO’s block sale—31,487 shares at $12.63—seeing it as a routine vesting exit that still signals insider confidence in the biotech’s growth prospects.

CEO buys 100k Kura Oncology shares, signaling confidence after Q2 earnings beat and bullish market sentiment—insider action could boost value.